使用 SGLT2 抑制剂治疗的尿路造口术患者局部感染引发的念珠菌败血症。
Candida sepsis from local infection in a patient with a urostomy on SGLT2 inhibitor therapy.
机构信息
Department of Infectious Diseases, Tropical Medicine, Nephrology and Rheumatology, St. Georg Hospital, Delitzscher Str. 141, D-04129 Leipzig, Germany; Kuratorium for Dialysis and Transplantation (KfH) Renal Unit, Hospital St. Georg, Leipzig, Germany.
Department of Infectious Diseases, Tropical Medicine, Nephrology and Rheumatology, St. Georg Hospital, Delitzscher Str. 141, D-04129 Leipzig, Germany.
出版信息
Int J Infect Dis. 2020 Sep;98:227-229. doi: 10.1016/j.ijid.2020.06.073. Epub 2020 Jun 24.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors exhibit impressive cardio-renal benefits in patients with a high cardiovascular risk. Genital yeast infections are important side effects of this class of drugs. We report a case of Candida glabrata sepsis secondary to a Candida infection of the urostomy of a patient on SGLT2 inhibitor therapy. In urostomy patients, one should critically evaluate the risk of mycotic infections against the cardiovascular and glycaemic benefits of SGLT2 inhibition. Urostomy patients without a high cardiovascular risk should not be treated with SGLT2 inhibitors.
钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在心血管风险较高的患者中表现出令人印象深刻的心脏肾脏获益。这类药物的一个重要副作用是生殖器酵母菌感染。我们报告了一例 SGLT2 抑制剂治疗患者的尿路造口处念珠菌感染导致近平滑念珠菌败血症的病例。对于尿路造口患者，应根据心血管和 SGLT2 抑制的血糖获益来仔细评估真菌感染的风险。没有高心血管风险的尿路造口患者不应使用 SGLT2 抑制剂。
Zotero 插件